#USA #Breakthrough T1D #Warwick, R.I. #Invictus Therapeutics #insulin analog

Collaborating for Better Diabetes Care

Invictus Therapeutics, a pioneering biotechnology firm, has entered into a significant collaboration with Breakthrough T1D, a frontrunner in type 1 diabetes research and advocacy. This partnership is set to propel the development of a game-changing next-generation insulin analog aimed at transforming insulin delivery systems.

On January 12, 2026, the companies announced they would use an Industry Discovery and Development Partnership (IDDP) grant from Breakthrough T1D to fund the upcoming first-in-human clinical trial of their lead investigational insulin analog. Known for its innovative engineered insulins designed for automated delivery, Invictus aims to create an ultra-rapid insulin that can closely mimic the physiological action of insulin while enhancing the performance of advanced delivery systems.

The Need for Advancement in Insulin Delivery

For many individuals managing type 1 diabetes (T1D), traditional insulin products can be a barrier to achieving optimal glucose control due to their limitations, particularly in automated insulin delivery systems. Current rapid-acting insulins do not fully satisfy the requirements for efficiency, stability, and user-friendliness. Invictus aims to alleviate these challenges with an insulin that is both room-temperature stable and ultra-rapid acting.

Robyn Day, Founder and CEO of Invictus Therapeutics, expressed excitement over this critical advancement, stating, "Our goal is to deliver an ultra-rapid, heat-resistant insulin analog that can operate reliably within automated insulin delivery platforms. This will empower patients to manage their diabetes with ease and effectiveness."

Clinical Trial Insights

The first trial phase will take place at Profil, Germany, an internationally recognized clinical research organization that specializes in diabetes studies. Known for its expertise in glucose-clamp methodology and pump-based insulin evaluations, Profil provides the ideal environment for testing Invictus's innovative insulin analog.

Dr. Amin Ghavami-Nejad, a senior scientist at Breakthrough T1D, emphasizes the potential of the new insulin, commenting, "Faster insulins can facilitate automated systems to attain superior clinical outcomes with minimal user engagement. Improving glucose management directly influences the quality of life for T1D patients."

Tackling Major Obstacles in Insulin Delivery

Invictus’s investigational insulin analog is pioneering in many aspects:

• - Ultra-rapid Action: Designed to mimic the body’s natural insulin release more closely.
• - Room-temperature Stability: Reduces the need for cold-chain storage, making it accessible for patients and manufacturers alike.
• - High-concentration Formulation: Optimized for pump efficiency, enabling extended use without frequent changes.

This innovative approach addresses significant barriers in the landscape of automated insulin delivery, striving for a future where individuals with diabetes can enjoy smoother management without the constant worry of glucose levels.

A Shared Vision for Future Advances

Only time will tell how this innovative technology transforms diabetes care, but both Invictus Therapeutics and Breakthrough T1D share a clear vision: a reliable, robust, and user-friendly system for managing type 1 diabetes. By integrating engineering advancements with compassionate care, they hope to redefine outcomes and elevate the daily lives of individuals living with T1D.